Effect of intracoronary prostaglandin E1 injection prior to percutaneous coronary intervention on myocardial microcirculation perfusion and clinical outcome in acute non-ST segment elevation myocardial infarction

Abstract

Objective To discuss the clinical effects and the major adverse cardiac events of intracoronary prostaglandin E1 injection prior to percutaneous coronary intervention(PCI) in early(within 24h of symptom onset) interventional treatment for patients with acute non-ST segment elevation myocardial infarction(NSTEMI). Methods 122 patients with NSTEMI who underwent early interventional treatment were divided into three groups according to the digital table: 41 cases in prostaglandin E1 group, 41 cases in nitroglycerin group, 40 cases in control group. The TIMI blood flow was compared among the three groups after PCI. All patients were followed up during 6 months about major adverse cardiac events(MACE) and the cardiac structure and function by echocardiography. Results After primary PCI, the corrected TIMI frame count(CTFC) was significantly better in the prostaglandin E1 group[(20.22±6.82)] than in the nitroglycerin group[(26.35±8.71)] and the control group[(27.02±9.65), t=6.451, 6.763, all P 0.05). All patients were followed up for 6 months, the LVDd in the prostaglandin E1 group[(46.8±3.7)mm] was significantly lower than that in the nitroglycerin group[(49.5±5.8)mm] and the control group[(50.2±4.9)mm, t=6.312, 5.893, all P 0.05). Conclusion Intracoronary administration of prostaglandin E1 injection prior to balloon dilation can significantly improve the myocardial microcirculation perfusion, and can decrease MACE in patients with NSTEMI who underwent early interventional treatment. Key words: Myocardial infarction; Myocardial perfusion imaging; Prostaglandin E1